Dylan Dunn

ORCID: 0009-0001-8158-5201
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Comparative and International Law Studies
  • Legal Education and Practice Innovations
  • Law, AI, and Intellectual Property
  • Intellectual Property and Patents
  • Cybersecurity and Cyber Warfare Studies
  • Artificial Intelligence in Law
  • Viral gastroenteritis research and epidemiology
  • Escherichia coli research studies
  • Freedom of Expression and Defamation
  • Intellectual Property Law
  • ICT Impact and Policies
  • Antibiotic Resistance in Bacteria
  • Effects of Radiation Exposure
  • Cybercrime and Law Enforcement Studies
  • Immune Cell Function and Interaction
  • Bacteriophages and microbial interactions
  • Hematopoietic Stem Cell Transplantation
  • Copyright and Intellectual Property

University of Maryland, Baltimore
2024-2025

Uniformed Services University of the Health Sciences
2020

Abstract Diarrhea caused by Shigella has been associated with high morbidity and mortality in young children worldwide. There are no licensed vaccines, those clinically advanced have restricted coverage as they elicit serotype-specific immunity while disease is multiple circulating serotypes. Our group had previously reported a close association between serum antibodies to the virulence factor VirG (or IcsA) clinical protection infected individuals. highly conserved among strains appealing...

10.1038/s41541-023-00797-6 article EN cc-by npj Vaccines 2024-01-02

Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccines based on conserved proteins are sought for their simplicity capacity prevent disease multiple serotypes. We previously reported broad protective of VirGα, surface-exposed domain virulence factor. Seeking...

10.1038/s41541-025-01064-6 article EN cc-by-nc-nd npj Vaccines 2025-01-13

Abstract Bone marrow failure and hematopoietic damage is one of the major consequences irradiation-induced lethality. There an immediate need to develop medical countermeasures (MCMs) combat We tested efficacy CDX-301, developed by Celldex Therapeutics Inc., in mice exposed Co-60 gamma total body irradiation (TBI). The drug demonstrated its both as a prophylactic countermeasure mitigator CD2F1 TBI. A single dose CDX-301 administered 24 h prior post–exposure conferred significant survival....

10.1038/s41598-020-58186-1 article EN cc-by Scientific Reports 2020-02-04
Coming Soon ...